Sanofi's $480M vaccine plant to set new benchmark in manufacturing agility

Sanofi Pasteur is gearing up with a series of investments into its global vaccine manufacturing network to tackle the future pandemics using futuristic manufacturing capabilities ensuring quality and scale.

- Hithaishi C Bhaskar

“Sanofi’s decision to invest 400 million euros to manufacture vaccines in Singapore marks our largest-ever investment to -date in Asia. This project is part of our innovation strategy, and we want to develop a centre of excellence for vaccine production in Singapore”. - Vincent Hingot Senior Vice President, Sanofi Pasteur, France

On April 12, 2021, a leading vaccine developer and manufacturer Sanofi Pasteur, in partnership with the Singapore Economic Development Board (EDB), announced a €400 million (USD $480 million) investment in Singapore to augment the vaccine production and boost the supply chain across the Asian region. The investment complements Sanofi’s commitment to tackle the future pandemics through a global vaccine drive using futuristic manufacturing capabilities ensuring quality and scale.

Sanofi Pasteur offers a portfolio of vaccines to protect children, adolescents, and adults from diseases such as influenza, infectious diseases, and endemic diseases. With 16,000 employees and an international network of 12 industrial sites dedicated to vaccine manufacturing, Sanofi Pasteur’s vaccines protect more than half a billion people in the world.

With this investments Sanofi Pasteur is gearing up with a series of investments into its global vaccine manufacturing network. Sanofi is transforming scientific innovation into healthcare solutions in 100 countries by focusing on massive vaccine production. The project is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry.